Zacks Investment Research on MSN
REGN soars 41% in six months: Is there more upside potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.
Investing News Network on MSN
Top 4 Canadian biotech stocks of 2025
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector ...
(NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent ® (dupilumab) for the ...
As of Thursday, December 18, Phathom Pharmaceuticals, Inc.’s PHAT share price has surged by 6.51%, which has investors questioning if this is right time to sell.
The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test ® (EST), marking a ...
Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...
Patients with eosinophilic esophagitis (EoE) often describe the condition as painful, disruptive and frightening. The rare chronic disease causes inflammation of the esophagus, leading to abdominal ...
Researchers at Children's Hospital of Philadelphia (CHOP) identified a potential new therapeutic target for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.
Esophagitis is inflammation of the esophagus, the tube that carries food from your mouth to your stomach, and can be caused by various factors including acid reflux, infections, and immune reactions.
VICTORIA, BC, Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results